Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlook
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook.
“Maravai has established an exceptionally strong foundation and we are building momentum toward our long-term goal of achieving high teens revenue growth with expanding EBITDA margins,” said Trey Martin, CEO of Maravai LifeSciences. “We are well-positioned in growing end-markets with innovative solutions across our Nucleic Acid Production (NAP) and Biologics Safety Testing (BST) segments, and we have the team, technologies, and financial position to execute on our comprehensive strategy to capture the opportunity.” Martin continued, “We are committed to translating extraordinary science into everyday miracles and creating value for our shareholders.”
At the event, Maravai shared:
Webcast Replay and Presentation Materials
A replay of the webcast and presentation materials from the event will be available on the “Investors” section of the Maravai website at https://investors.maravai.com/.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies.
Forward-Looking Statements
This press release contains, and Maravai’s officers and representatives may from time-to-time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai’s 2028 financial targets; favorable macro trends; the pipeline progression of Maravai’s customers’ development programs; growth opportunities, including inorganic growth; and future innovations, constitute forward-looking statements and are identified by words like “outlook,” “goal,” “trend,” “target,” “believe,” “expect,” “see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, continued demand for our COVID-19 related products and services, which currently comprise a significant portion of our revenue, and the other risks and uncertainties described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
CONTACT: Contact Information: Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@maravai.com Media Contact: Sara Michelmore MacDougall Advisors +1 781-235-3060 maravai@macdougall.bio
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…